BrainChild Bio, Inc.
BrainChild Bio develops CAR T-cell therapies for central nervous system tumors, prioritizing pediatric brain cancers such as diffuse intrinsic pontine glioma and extending its pipeline to adult tumors including glioblastoma and brain metastases. It aims to create safe and effective treatment options for children and adults with incurable brain tumors.
Facts
- Sectors
- Biotechnology Research
- Employees
- 11–50
- Stage
- Series A
- Founders
- Michael Jensen, MD
Is this your organization? Claim it
Stoke Space’s $1B Series E Propels Seattle Metro to $3.5B in VC Funding Across 94 Q3 Deals
Seattle-area VC activity surged in Q3 as Stoke Space led with a $1 billion Series E initial close and the region raised $3.5 billion across 94 deals, its strongest quarter in at least a decade.
Todd Bishop unveils GeekWire 200: Temporal Technologies tops Seattle-area startup rankings as Stoke Space climbs after ~$1B raise
Todd Bishop presents the latest GeekWire 200 ranking of top privately held Pacific Northwest tech startups, highlighting AI infrastructure gains and notable movers such as Temporal Technologies taking No. 1 and Stoke Space rising after a ~$1B raise.
Jacob Colker announces Seattle startups score major wins: Stoke Space $1B raise, BrainChild Bio $116M, Nuance Labs $50M, Helion expands
A roundup by Jacob Colker highlights major Seattle-area tech and biotech funding and growth: Stoke Space raised $1B (now $2.3B) for reusable rockets, BrainChild Bio $116M for a CAR-T DIPG trial, General Robotics offers rapid robot deployment, Helion expands amid fusion commercialization with 800+ employees, and Nuance Labs raised $50M for multimodal AI.
By BrainChild Bio, Inc.
See all 7BrainChild Bio Raises $116M Series A to Fund Pivotal Phase 2 Trial of BCB-276 CAR T Therapy for DIPG
BrainChild Bio, spun out of Seattle Children’s, is advancing B7-H3–targeting CAR T-cell therapies for incurable pediatric brain tumors and has raised $116 million to fund a pivotal Phase 2 trial of BCB-276 for DIPG.
BrainChild Bio to pursue multi-center Phase 2 pivotal trial of BCB-276, an autologous B7-H3 CAR T therapy for DIPG after positive FDA meeting and Phase 1 Nature Medicine data
BrainChild Bio will advance BCB-276, an autologous B7-H3–targeting CAR T-cell therapy for diffuse intrinsic pontine glioma (DIPG), into a multi-center Phase 2 pivotal trial following a positive FDA Type B meeting and supportive Phase 1 data published in Nature Medicine. The company aims to use this accelerated path toward a Biologics License Application to bring a potential treatment to children and young adults with no approved options.
BrainChild Bio launches pivotal Phase 2 ILLUMINATE trial of BCB-276 CAR T for newly diagnosed pediatric DIPG to support BLA
BrainChild Bio has launched the ILLUMINATE Phase 2 pivotal trial of BCB-276, a B7-H3-targeted autologous CAR T therapy for newly diagnosed pediatric DIPG, enrolling at six U.S. pediatric oncology centers to evaluate efficacy and safety and support a future BLA.
People
-
Michael Jensen Founder, Chief Scientific Officer
-
Steven Brugger Executive, Chief Executive Officer
Online
Questions about BrainChild Bio, Inc.
What is BrainChild Bio, Inc.?
BrainChild Bio, Inc. is a startup developing CAR T-cell therapies for central nervous system tumors in children and adults.
What is BrainChild Bio, Inc. known for?
BrainChild Bio, Inc. prioritizes pediatric brain cancers such as diffuse intrinsic pontine glioma, with a pipeline extending to adult tumors including glioblastoma and brain metastases.
Who are the people behind BrainChild Bio, Inc.?
Michael Jensen is founder and chief scientific officer of BrainChild Bio, Inc. Steven Brugger is chief executive officer.
Who invested in BrainChild Bio, Inc., and how much has it raised?
Members of Seattle Flow see BrainChild Bio, Inc.'s funding rounds, amounts and investors on its Funding tab. Joining is free.
How many people work at BrainChild Bio, Inc.?
BrainChild Bio, Inc. has 11–50 employees.